AIMS: The pathogenesis of cardiac allograft vasculopathy (CAV) remains complex and may involve multiple mechanisms. We tested the hypothesis that the multilayer (ML) appearance, an intravascular ultrasound (IVUS) finding suggestive of repetitive thrombosis, is associated with plaque progression in heart transplant (HTx) recipients. METHODS AND RESULTS: Our study population consisted of 132 HTx recipients undergoing at least two grayscale and virtual histology (VH)-IVUS examinations. A retrospective serial analysis was performed between the first (baseline) and the last (follow-up) IVUS data during a median follow-up of 3.0 years. The subjects were divided into two groups based on the presence of the ML appearance on the baseline IVUS. At baseline, subjects with ML appearance (n = 38) had a longer time elapsed since transplant, larger vessel volume, and larger plaque volume than those without (n = 94) (all P < 0.01). Intraluminal thrombi and plaque ruptures were identified only in subjects with ML appearance (P < 0.01 vs. those without). More subjects with ML appearance at baseline developed subsequent ML formation compared with those without [21 (55%) vs. 22 (23%), P < 0.01] during follow-up. There was an increase in plaque volume, necrotic core volume, and dense calcium volume in subjects with ML appearance (all P < 0.01 vs. those without). Multivariable linear regression analysis showed that ML appearance was a potential predictor of plaque progression (regression coefficient 0.28, 95% CI 0.10-0.45, P < 0.01). CONCLUSIONS: The current study demonstrates that a finding of ML appearance, indicative of repeated episodes of mural thrombosis, is not infrequent in asymptomatic HTx recipients and possibly contributes to progression of CAV.
AIMS: The pathogenesis of cardiac allograft vasculopathy (CAV) remains complex and may involve multiple mechanisms. We tested the hypothesis that the multilayer (ML) appearance, an intravascular ultrasound (IVUS) finding suggestive of repetitive thrombosis, is associated with plaque progression in heart transplant (HTx) recipients. METHODS AND RESULTS: Our study population consisted of 132 HTx recipients undergoing at least two grayscale and virtual histology (VH)-IVUS examinations. A retrospective serial analysis was performed between the first (baseline) and the last (follow-up) IVUS data during a median follow-up of 3.0 years. The subjects were divided into two groups based on the presence of the ML appearance on the baseline IVUS. At baseline, subjects with ML appearance (n = 38) had a longer time elapsed since transplant, larger vessel volume, and larger plaque volume than those without (n = 94) (all P < 0.01). Intraluminal thrombi and plaque ruptures were identified only in subjects with ML appearance (P < 0.01 vs. those without). More subjects with ML appearance at baseline developed subsequent ML formation compared with those without [21 (55%) vs. 22 (23%), P < 0.01] during follow-up. There was an increase in plaque volume, necrotic core volume, and dense calcium volume in subjects with ML appearance (all P < 0.01 vs. those without). Multivariable linear regression analysis showed that ML appearance was a potential predictor of plaque progression (regression coefficient 0.28, 95% CI 0.10-0.45, P < 0.01). CONCLUSIONS: The current study demonstrates that a finding of ML appearance, indicative of repeated episodes of mural thrombosis, is not infrequent in asymptomatic HTx recipients and possibly contributes to progression of CAV.
Authors: Jun-ichi Kotani; Gary S Mintz; Prithviraj B Rai; Chrysoula K Pappas; Natalie Gevorkian; Anh B Bui; Augusto D Pichard; Lowell F Satler; William O Suddath; Ron Waksman; John R Laird; Kenneth M Kent; Neil J Weissman Journal: J Am Coll Cardiol Date: 2004-11-16 Impact factor: 24.094
Authors: Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2011-10 Impact factor: 10.247
Authors: Marc Hartmann; Clemens von Birgelen; Gary S Mintz; Martin G Stoel; Holger Eggebrecht; Heinrich Wieneke; Martin Fahy; Till Neumann; Job van der Palen; Hans W Louwerenburg; Patrick M J Verhorst; Raimund Erbel Journal: J Am Coll Cardiol Date: 2006-07-12 Impact factor: 24.094
Authors: Edward B Diethrich; M Pauliina Margolis; Donald B Reid; Allen Burke; Venkatesh Ramaiah; Julio A Rodriguez-Lopez; Grayson Wheatley; Dawn Olsen; Renu Virmani Journal: J Endovasc Ther Date: 2007-10 Impact factor: 3.487
Authors: P Kearney; R Erbel; H J Rupprecht; J Ge; L Koch; T Voigtländer; P Stähr; G Görge; J Meyer Journal: Eur Heart J Date: 1996-05 Impact factor: 29.983
Authors: Kozo Okada; William F Fearon; Helen Luikart; Hideki Kitahara; Kyuhachi Otagiri; Shigemitsu Tanaka; Takumi Kimura; Paul G Yock; Peter J Fitzgerald; Alan C Yeung; Hannah A Valantine; Kiran K Khush; Yasuhiro Honda Journal: J Am Coll Cardiol Date: 2016-07-26 Impact factor: 24.094
Authors: Tor Skibsted Clemmensen; Niels Ramsing Holm; Hans Eiskjær; Steen Hvitfeldt Poulsen; Michael Maeng; Christian Juhl Terkelsen; Evald Høj Christiansen Journal: Case Rep Transplant Date: 2016-11-17
Authors: Dongmei Wei; Sander Trenson; Jan M Van Keer; Jesus Melgarejo; Ella Cutsforth; Lutgarde Thijs; Tianlin He; Agnieszka Latosinska; Agnieszka Ciarka; Thomas Vanassche; Lucas Van Aelst; Stefan Janssens; Johan Van Cleemput; Harald Mischak; Jan A Staessen; Peter Verhamme; Zhen-Yu Zhang Journal: ESC Heart Fail Date: 2022-01-10